Bacterial Strain Composition for CD8+ T-Cell Induction

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current approaches to modulate the human microbiota and enhance immune responses for cancer immunotherapy and vaccine efficacy are limited, particularly in addressing microbiome modifications that lead to infectious diseases and cancer, with existing interventions having adverse effects and limited efficacy.

Innovation Solution

A composition of purified bacterial strains, including Phascolarctobacterium faecium, Fusobacterium ulcerans, and Bacteroides dorei, is administered to induce interferon gamma-producing CD8+ T cells, promoting immune system activation and surveillance against infections and cancer cells.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional microbiota modulation approaches (antibiotics, prebiotics, probiotics, fecal transplants) are used, then immune response can be modulated, but adverse effects and limited efficacy occur

Engineering Contradiction:

Improveefficacy of immune response modulationVSAvoidadverse effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent changes the parameter of bacterial strain selection by identifying and using specific strains (Phascolarctobacterium faecium, Fusobacterium ulcerans, Bacteroides dorei) that produce particular metabolites capable of inducing CD8+ T cells, rather than using conventional broad-spectrum approaches. This targeted parameter change achieves reliable immune modulation without the adverse effects of antibiotics or unselected probiotics.

Inventive Principle:

Principle #35Parameter changes

2Reliability

If cancer immunotherapy is administered, then survival rates improve, but a large percentage of patients do not respond

Engineering Contradiction:

Improveresponse rate to cancer immunotherapyVSAvoidapplicability across patient populations

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent applies preliminary action by administering specific bacterial strains before or during cancer immunotherapy to pre-condition the immune system. The bacterial metabolites induce CD8+ T cell proliferation in advance, creating a more responsive immune state that enhances subsequent immunotherapy effectiveness across diverse patient populations.

Inventive Principle:

Principle #10Preliminary action

3Adaptability or versatility

If microbiota modification is caused by antibiotics or other factors, then immune system development is affected, but loss of tolerance and excessive inflammatory responses occur

Engineering Contradiction:

Improveimmune system developmentVSAvoidloss of tolerance and excessive inflammation

Core Design Contradiction:

Adaptability or versatilityVSObject-generated harmful factors

Solution Approach 1:

The patent converts the harmful effect of microbiota modification into a benefit by using controlled administration of specific bacterial strains that produce metabolites (such as butyrate) known to regulate immune tolerance. These metabolites actively suppress excessive inflammation and maintain tolerance while still promoting appropriate immune responses, effectively reversing the harmful consequences of uncontrolled microbiota changes.

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Data Source

PatentUS11633465B2Compositions and methods for the induction of CD8+ T-cells

Publication Date: 2023.04.25 KEIO UNIV

AI summary

Provided herein are compositions and methods for the induction and/or proliferation of CD8+ T-cells. The disclosure also provides methods of treatment of diseases that can be treated by the induction and/or proliferation of CD8+ T-cells.